WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) recently showcased promising data on istaroxime, an investigational treatment for early cardiogenic shock, at the Cardiovascular Clinical Trials Conference in Washington, DC. The presentation, delivered by renowned cardiogenic shock expert Dr. Alexandre Mebazaa, highlighted the findings from the Phase 2b SEISMiC B study.
Cardiogenic shock, often caused by heart failure, is marked by dangerously low blood pressure that compromises blood flow to vital organs, leading to high morbidity and mortality rates. Istaroxime offers a novel approach, aiming to improve heart function and stabilize blood pressure while maintaining renal function.
The SEISMiC B study results revealed that istaroxime could significantly and rapidly increase systolic blood pressure and improve cardiac output without raising heart rate or increasing the risk of severe arrhythmias. These effects are critical in reversing early cardiogenic shock and improving patient outcomes.
“We are pleased that istaroxime is receiving positive attention based on the recent clinical trial results in treating patients with early cardiogenic shock,” said Dr. Steve Simonson, Chief Medical Officer and Senior Vice President of Windtree Therapeutics. “We believe that pharmacologic innovation is needed in treating patients with cardiogenic shock. Currently available drugs can have unwanted side effects and poor outcomes.”
Dr. Simonson noted the distinct advantages of istaroxime, pointing to its safety and efficacy profile observed in two Phase 2 studies on cardiogenic shock. “Both have demonstrated the unique characteristics of rapidly and significantly increasing systolic blood pressure and improving cardiac output without increasing heart rate. Additionally, we have not seen an increase in clinically significant arrhythmias, and istaroxime has maintained or improved renal function.”
The company plans to advance istaroxime into Phase 3 trials, building on the significant progress made. With its first-in-class status and favorable safety profile, istaroxime represents a potential breakthrough for patients experiencing early cardiogenic shock due to heart failure—a condition with limited treatment options.
Windtree Therapeutics remains committed to addressing the unmet needs in cardiogenic shock through innovative solutions that could transform care for thousands of patients. “We look forward to progressing istaroxime toward Phase 3 in cardiogenic shock,” Simonson concluded.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.